AstraZeneca Zegfrovy Deal: AstraZeneca Licenses Dizal’s Oral EGFR Inhibitor for Lung Cancer in Up to $1.5 Billion Agreement
AstraZeneca has secured exclusive worldwide rights to Zegfrovy (sunvozertinib), Dizal Pharmaceutical’s oral EGFR inhibitor for EGFR exon 20 insertion non-small cell lung cancer, in a deal worth up to $1.5 billion. The agreement strengthens AstraZeneca’s EGFR-mutated lung cancer portfolio ahead of potential first-line expansion.
